2-(chloromethyl)-5,7-dimethyl[1,2,4]triazolo[1,5-a]pyridine | 1201687-94-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 三唑并吡啶类
• 英文名称: 2-(chloromethyl)-5,7-dimethyl[1,2,4]triazolo[1,5-a]pyridine
• 英文别名: 2-(Chloromethyl)-5,7-dimethyl-[1,2,4]triazolo[1,5-a]pyridine
• CAS: 1201687-94-6
• 化学式: C₉H₁₀ClN₃
• 分子量: 195.651
• InChiKey: ZURNRHMVTVGBCK-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.9
• 重原子数：
  13
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  30.2
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  2-(chloromethyl)-5,7-dimethyl[1,2,4]triazolo[1,5-a]pyridine 在 N,N-二异丙基乙胺 、 Methanaminium,N-[(dimethylamino)(3H-1,2,3-triazolo[4,5-b]pyridin-3-yloxy)methylene]-N-methyl-, hexafluorophosphate(1-) 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 56.0h， 生成 1-(2,3-dihydro-1H-imidazo[1,2-a]benzimidazol-1-yl)-2-(5,7-dimethyl[1,2,4]triazolo[1,5-a]pyridin-2-yl)ethan-1-one
  参考文献：
  名称：

  新型2,3-二氢-1H-咪唑并[1,2-a]苯并咪唑衍生物作为磷酸二酯酶10A抑制剂的合成，SAR研究和生物学评估。

  摘要：

  磷酸二酯酶10A（PDE10A）抑制剂是基于二氢-咪唑并苯并咪唑支架设计和合成的。化合物5a表现出中等的抑制活性和良好的通透性，但不利于脑部渗透的高P-糖蛋白（P-gp）责任。我们进行了优化研究，以提高P-gp外排率和PDE10A抑制活性。结果，鉴定出具有改善的P-gp耐受性和高PDE10A抑制活性的6d。化合物6d还显示出令人满意的脑渗透，抑制苯环利定诱导的运动过度和改善MK-801诱导的工作记忆障碍。

  DOI：

  10.1016/j.bmc.2019.07.010
• 作为产物：
  描述：

  2-imino-4,6-dimethyl-2H-pyridin-1-ylamine 在 氯化亚砜 、 sodium hydroxide 作用下， 以 乙醇 、 二氯甲烷 为溶剂， 反应 9.0h， 生成 2-(chloromethyl)-5,7-dimethyl[1,2,4]triazolo[1,5-a]pyridine
  参考文献：
  名称：

  [EN] NOVEL PHENYLIMIDAZOLE DERIVATIVES AS PDE10A ENZYME INHIBITORS
  [FR] NOUVEAU DÉRIVÉS DE PHÉNYLIMIDAZOLE CONVENANT COMME INHIBITEURS DE L'ENZYME PDE10A

  摘要：

  该发明涉及一种PDE10A酶抑制剂的化合物。该发明提供了一种包含该发明化合物的治疗有效量和药用可接受载体的药物组合物。本发明还提供了一种制备公式（I）化合物的方法。本发明还提供了一种治疗患有神经退行性疾病的受试者的方法，包括向受试者投与公式（I）化合物的治疗有效量。本发明还提供了一种治疗患有药物成瘾的受试者的方法，包括向受试者投与公式（I）化合物的治疗有效量。本发明还提供了一种治疗患有精神障碍的受试者的方法，包括向受试者投与公式（I）化合物的治疗有效量。

  公开号：

  WO2009152825A1

文献信息

• NOVEL PHENYLIMIDAZOLE DERIVATIVES AS PDE10A ENZYME INHIBITORS
  申请人：Ritzén Andreas

  公开号：US20100016303A1

  公开（公告）日：2010-01-21

  This invention is directed to compounds, which are PDE10A enzyme inhibitors. The invention provides a pharmaceutical composition comprising a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier. The present invention also provides processes for the preparation of the compounds of formula I. The present invention further provides a method of treating a subject suffering from a neurodegenerative disorder comprising administering to the subject a therapeutically effective amount of a compound of formula I. The present invention also provides a method of treating a subject suffering from a drug addiction comprising administering to the subject a therapeutically effective amount of a compound of formula I. The present invention further provides a method of treating a subject suffering from a psychiatric disorder comprising administering to the subject a therapeutically effective amount of a compound of formula I.

  这项发明涉及一类PDE10A酶抑制剂化合物。该发明提供了一种包含所述发明化合物的治疗有效量和药学可接受载体的药物组合物。本发明还提供了制备式I化合物的方法。本发明还提供了一种治疗患有神经退行性疾病的受试者的方法，包括向受试者投予式I化合物的治疗有效量。本发明还提供了一种治疗患有药物成瘾的受试者的方法，包括向受试者投予式I化合物的治疗有效量。本发明还提供了一种治疗患有精神障碍的受试者的方法，包括向受试者投予式I化合物的治疗有效量。
• [EN] HETEROAROMATIC PHENYLIMIDAZOLE DERIVATIVES AS PDE10A ENZYME INHIBITORS<br/>[FR] DÉRIVÉS HÉTÉROAROMATIQUES DE PHÉNYLIMIDAZOLE EN TANT QU'INHIBITEURS DE L'ENZYME PDE10A
  申请人：LUNDBECK & CO AS H

  公开号：WO2011072694A1

  公开（公告）日：2011-06-23

  This invention is directed to compounds, which are PDE10A enzyme inhibitors. The invention provides a pharmaceutical composition comprising a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier. The present invention also provides processes for the preparation of the compounds of formula I. The present invention further provides a method of treating a subject suffering from a neurodegenerative disorder comprising administering to the subject a therapeutically effective amount of a compound of formula I. The present invention also provides a method of treating a subject suffering from a drug addiction comprising administering to the subject a therapeutically effective amount of a compound of formula I. The present invention further provides a method of treating a subject suffering from a psychiatric disorder comprising administering to the subject a therapeutically effective amount of a compound of formula I.

  本发明涉及化合物，这些化合物是PDE10A酶抑制剂。本发明提供了一种药物组合物，包含本发明化合物的治疗有效量和药学上可接受的载体。本发明还提供了制备式I化合物的方法。本发明进一步提供了一种治疗患有神经退行性疾病的主体的方法，包括向该主体施用式I化合物的治疗有效量。本发明还提供了一种治疗患有药物成瘾的主体的方法，包括向该主体施用式I化合物的治疗有效量。本发明进一步提供了一种治疗患有精神疾病的主体的方法，包括向该主体施用式I化合物的治疗有效量。
• Heteroaromatic Phenylimidazole derivatives as PDE10A enzyme inhibitors
  申请人：Püschl Ask

  公开号：US20120309714A1

  公开（公告）日：2012-12-06

  This invention is directed to compounds, which are PDE10A enzyme inhibitors. The invention provides a pharmaceutical composition comprising a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier. The present invention also provides processes for the preparation of the compounds of formula I. The present invention further provides a method of treating a subject suffering from a neurodegenerative disorder comprising administering to the subject a therapeutically effective amount of a compound of formula I. The present invention also provides a method of treating a subject suffering from a drug addiction comprising administering to the subject a therapeutically effective amount of a compound of formula I. The present invention further provides a method of treating a subject suffering from a psychiatric disorder comprising administering to the subject a therapeutically effective amount of a compound of formula I.

  本发明涉及一种PDE10A酶抑制剂化合物。该发明提供了一种药物组成物，包括本发明化合物的治疗有效量和药学上可接受的载体。本发明还提供了制备式I化合物的方法。本发明还提供了一种治疗神经退行性疾病的方法，包括向受试者施用式I化合物的治疗有效量。本发明还提供了一种治疗药物成瘾的方法，包括向受试者施用式I化合物的治疗有效量。本发明还提供了一种治疗精神障碍的方法，包括向受试者施用式I化合物的治疗有效量。
• Novel Phenylimidazole Derivatives as PDE10A Enzyme Inhibitors
  申请人：H. Lundbeck A/S

  公开号：US20150190395A1

  公开（公告）日：2015-07-09

  This invention is directed to compounds, which are PDE10A enzyme inhibitors. The invention provides a pharmaceutical composition comprising a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier. The present invention also provides processes for the preparation of the compounds of formula I. The present invention further provides a method of treating a subject suffering from a neurodegenerative disorder comprising administering to the subject a therapeutically effective amount of a compound of formula I. The present invention also provides a method of treating a subject suffering from a drug addiction comprising administering to the subject a therapeutically effective amount of a compound of formula I. The present invention further provides a method of treating a subject suffering from a psychiatric disorder comprising administering to the subject a therapeutically effective amount of a compound of formula I.

  本发明涉及一种PDE10A酶抑制剂化合物。该发明提供了一种药物组合物，包括本发明的化合物的治疗有效量和药学上可接受的载体。本发明还提供了制备式I化合物的方法。本发明进一步提供了一种治疗神经退行性疾病患者的方法，包括向患者施用式I化合物的治疗有效量。本发明还提供了一种治疗药物成瘾患者的方法，包括向患者施用式I化合物的治疗有效量。本发明进一步提供了一种治疗精神障碍患者的方法，包括向患者施用式I化合物的治疗有效量。
• HETEROAROMATIC PHENYLIMIDAZOLE DERIVATIVES AS PDE10A ENZYME INHIBITORS
  申请人：H. Lundbeck A/S

  公开号：EP2513107A1

  公开（公告）日：2012-10-24